Medtronic reported FY 1Q25 orthopedic sales of $808.3 million, up 6.3% compared to the first quarter of fiscal 2024.
The company continues to outperform the spine market with high single-digit growth driven by the AiBLE ecosystem, the Catalyft expandable interbody and the ModuLeX spinal system. Grafton bone graft drove orthobiologic sales in the quarter.
“Our spine business continues to outperform the market,” said Medtronic CEO Geoff Martha. “Our sustained share capture is driven by our AiBLE ecosystem. Its differentiated features and sheer scale around the world are a winning formula for our spine business. It’s good for patients and surgeons, and it’s changing the competitive dynamics in the spine.”
The company expects total sales growth between 4.5% and 5% for fiscal 2025.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
FY 1Q25
FY 1Q24
$ Chg
% Chg
Spine
$575.4
$537.8
$37.6
7%
Orthobiologics
$113.8
$106.9
$6.9
6.5%
Enabling Technology
$33.2
$32.2
$1.0
3%
Other
$85.9
$83.2
$2.7
3.2%
Total
$808.3
$760.1
$48.2
6.3%
Orthopedic Sales by Geography
FY 1Q25
FY 1Q24
$ Chg
% Chg
US
$602.5
$565.7
$36.8
6.5%
OUS
$205.8
$194.3
$11.4
5.9%
EMEA
$103.1
$95.4
$7.7
8%
APAC
$82.9
$79.8
$3.0
3.8%
ROW
$19.9
$19.1
$0.7
3.9%
Total
$808.3
$760.1
$48.2
6.3%
Company Earnings
Amt
% of Sales
Sales
$7,915.0
Cost of Sales
$2,761.0
34.9%
Selling and Admin
$2,655.0
33.5%
R & D
$676.0
8.5%
Other
$781.0
9.9%
Net Earnings
$1,042.0
13.2%
Medtronic reported FY 1Q25 orthopedic sales of $808.3 million, up 6.3% compared to the first quarter of fiscal 2024.
The company continues to outperform the spine market with high single-digit growth driven by the AiBLE ecosystem, the Catalyft expandable interbody and the ModuLeX spinal system. Grafton bone graft drove orthobiologic sales...
Medtronic reported FY 1Q25 orthopedic sales of $808.3 million, up 6.3% compared to the first quarter of fiscal 2024.
The company continues to outperform the spine market with high single-digit growth driven by the AiBLE ecosystem, the Catalyft expandable interbody and the ModuLeX spinal system. Grafton bone graft drove orthobiologic sales in the quarter.
“Our spine business continues to outperform the market,” said Medtronic CEO Geoff Martha. “Our sustained share capture is driven by our AiBLE ecosystem. Its differentiated features and sheer scale around the world are a winning formula for our spine business. It’s good for patients and surgeons, and it’s changing the competitive dynamics in the spine.”
The company expects total sales growth between 4.5% and 5% for fiscal 2025.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
FY 1Q25
FY 1Q24
$ Chg
% Chg
Spine
$575.4
$537.8
$37.6
7%
Orthobiologics
$113.8
$106.9
$6.9
6.5%
Enabling Technology
$33.2
$32.2
$1.0
3%
Other
$85.9
$83.2
$2.7
3.2%
Total
$808.3
$760.1
$48.2
6.3%
Orthopedic Sales by Geography
FY 1Q25
FY 1Q24
$ Chg
% Chg
US
$602.5
$565.7
$36.8
6.5%
OUS
$205.8
$194.3
$11.4
5.9%
EMEA
$103.1
$95.4
$7.7
8%
APAC
$82.9
$79.8
$3.0
3.8%
ROW
$19.9
$19.1
$0.7
3.9%
Total
$808.3
$760.1
$48.2
6.3%
Company Earnings
Amt
% of Sales
Sales
$7,915.0
Cost of Sales
$2,761.0
34.9%
Selling and Admin
$2,655.0
33.5%
R & D
$676.0
8.5%
Other
$781.0
9.9%
Net Earnings
$1,042.0
13.2%
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Copy to clipboard 
